Lazard Asset Management LLC Reduces Holdings in Prestige Consumer Healthcare Inc. $PBH

Lazard Asset Management LLC lowered its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 70.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,993 shares of the company’s stock after selling 16,299 shares during the period. Lazard Asset Management LLC’s holdings in Prestige Consumer Healthcare were worth $414,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in shares of Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after purchasing an additional 91,710 shares during the last quarter. State Street Corp raised its position in shares of Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after purchasing an additional 27,721 shares during the last quarter. Morgan Stanley lifted its stake in Prestige Consumer Healthcare by 6.3% in the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after buying an additional 71,078 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Prestige Consumer Healthcare by 5.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after buying an additional 35,126 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after buying an additional 115,459 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of several recent research reports. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $54.92 on Friday. The stock’s 50 day moving average price is $48.82 and its 200 day moving average price is $56.06. The firm has a market capitalization of $2.60 billion, a PE ratio of 15.38, a price-to-earnings-growth ratio of 1.69 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.25 and a current ratio of 3.23. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to the consensus estimate of $250.34 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter last year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.6 EPS for the current fiscal year.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).